Liminatus Pharma Enters Material Definitive Agreement
Ticker: LIMNW · Form: 8-K · Filed: Jul 17, 2025 · CIK: 1971387
| Field | Detail |
|---|---|
| Company | Liminatus Pharma, Inc. (LIMNW) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-securities, unregistered-sales
TL;DR
Liminatus Pharma just signed a big deal for unregistered equity sales.
AI Summary
Liminatus Pharma, Inc. entered into a material definitive agreement on July 16, 2025, related to unregistered sales of equity securities. The company, formerly known as Iris Parent Holding Corp., is incorporated in Delaware and based in La Palma, California.
Why It Matters
This filing indicates a significant transaction involving the company's equity, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can sometimes indicate financial distress or a need for capital, which carries inherent risks.
Key Players & Entities
- Liminatus Pharma, Inc. (company) — Registrant
- Iris Parent Holding Corp. (company) — Former Company Name
- July 16, 2025 (date) — Date of Report
- La Palma, CA (location) — Principal Executive Office Location
FAQ
What type of material definitive agreement did Liminatus Pharma enter into?
The filing indicates the agreement is related to unregistered sales of equity securities.
When was this agreement reported?
The report date is July 17, 2025, with the earliest event reported on July 16, 2025.
What was Liminatus Pharma's former name?
Liminatus Pharma, Inc. was formerly known as Iris Parent Holding Corp.
Where is Liminatus Pharma, Inc. headquartered?
The company's principal executive offices are located at 6 Centerpointe Drive #625, La Palma, CA 90623.
What is Liminatus Pharma's Standard Industrial Classification code?
The SIC code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding Liminatus Pharma, Inc. (LIMNW).